Drug patent litigation isn’t just about the molecule—it’s about the design choices around it.
If you’re a pharma leader, IP counsel, or R&D executive, you already know the headline version: “design around” is the strategy to avoid infringement wh…

Drug patent litigation isn’t just about molecules—it’s about design choices.
In pharma, “design around” sounds like a strategy. In practice, it’s a discipline: a way to translate patent language into formulation decisions, development timelines, and …

Pharma has a $300 billion question it can’t afford to misread: Is the clock being restored—or adjusted?
That distinction sounds like legal fine print. In practice, it can decide whether a blockbuster gets another year of exclusivity, whether a generic …

Pharma has a $300B problem—and it’s not just about patents. It’s about time.
In the U.S., the patent system doesn’t merely grant exclusivity; it also tries to compensate for delays outside a drugmaker’s control. That’s where two concepts—patent term ad…

Pharma executives don’t lose in Eurasia because they “missed a filing.”
They lose because they misunderstood the system.
Drug patents in Eurasia aren’t just a legal checklist—they’re a moving, multi-jurisdiction chessboard where timing, translation, pr…

Pharmaceutical patent strategy is often discussed like a binary choice: fight, settle, or walk away.
But the real world is messier—and more expensive.
In a recent DrugPatentWatch piece, the “cut / keep / cash” decision matrix reframes patent portfolios…

The most valuable window in pharma isn’t after launch—it’s before the patent clock runs out.
In commercial market access, timing is destiny. But most business development teams still behave like they’re selling after the product story is already writte…

Before You Launch: The Freedom-to-Operate Checklist That Can Save Your Company (and Your Timeline)
In pharma, “almost ready” can be the most expensive phrase in the industry.
You can have the right molecule, the right trial data, the right manufacturin…

Exercise has been shown to impact aspirin’s antiplatelet effect, although the relationship is complex and not yet fully… https://www.Drugchatter.com/chat/3569/how-does-exercise-impact-aspirin’s-antiplatelet-effect/

Exercise has been shown to impact aspirin’s antiplatelet effect, although the relationship is complex and not yet fully… https://www.Drugchatter.com/chat/3569/how-does-exercise-impact-aspirin’s-antiplatelet-effect/